Security Reports > Aerie Pharmaceuticals
Aerie Pharmaceuticals
Data Breaches, Cyber Attacks and Security Report
https://aeriepharma.com ᛫
Last updated September 25, 2020
https://aeriepharma.com ᛫
Last updated September 25, 2020
UpGuard's Cyber Security Ratings range from 0 to 950. The higher the score, the more likely Aerie Pharmaceuticals is implementing good security practices.
Aerie Pharmaceuticals Inc. (NASDAQ: AERI) is a publicly traded, clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye.
This report shows a preliminary security rating for Aerie Pharmaceuticals. UpGuard scans billions of digital assets daily, in depth, across thousands of vectors. Data leak detection, vulnerability scanning and identity breach detection are just some of the advanced capabilities offered by the UpGuard platform.
Get a deeper scan →Read more about the latest issues in cybersecurity
Compare Aerie Pharmaceuticals's security performance with other companies